Halozyme Therapeutics, Inc. (HALO)

62.21 +0.31 (+0.50%) USD  |  NASDAQ  |  Dec 12, 16:00
62.21 0.00 (0.00%) After-Hours: 20:00
More

Halozyme Therapeutics Research and Development Expense (Annual): 79.05M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Merck & Co., Inc. 15.79B
ANI Pharmaceuticals, Inc. 44.58M
Bristol Myers Squibb Co. 9.782B
Johnson & Johnson 17.26B
AIM ImmunoTech, Inc. 6.149M